Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12442639 | 0.91 | NAMPT (0.57) | ACHEHTTALDH1A1LMNASCD5 | |
| SCHEMBL1808901 | 0.90 | MGLL (0.63) | ACHEHTTALDH1A1LMNAEPHX2 | |
| SCHEMBL693657 | 0.90 | ALDH1A1 (0.55) | ACHEHTTALDH1A1LMNASCD5 | |
| SCHEMBL13846190 | 0.87 | KMT2A (0.57) | HTTALDH1A1LMNASCD5KMT2A | |
| SCHEMBL8357204 | 0.86 | EPHX2 (0.61) | ACHEHTTALDH1A1LMNASCD5 | |
| SCHEMBL5271411 | 0.85 | EPHX2 (0.59) | SCD5EPHX2SRD5A1 | |
| SCHEMBL913079 | 0.84 | L3MBTL3 (0.56) | HTTALDH1A1LMNAL3MBTL3L3MBTL1 | |
| SCHEMBL4578845 | 0.83 | EPHX2 (0.58) | SCD5EPHX2SRD5A1 | |
| SCHEMBL27748883 | 0.82 | ACHE (0.68) | ACHEALDH1A1LMNAEPHX1L3MBTL3 | |
| SCHEMBL4678438 | 0.82 | ACHE (0.63) | ACHEEPHX1L3MBTL3L3MBTL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | MAPK1, NOS1, NOS2 | ACHE 1148/4885HTT 2432/4885ALDH1A1 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.